Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22157826 | 0.87 | CYP2D6 (0.33) | CA1CA2GAAHDAC6HDAC1 | |
| SCHEMBL28412217 | 0.87 | CYP2D6 (0.33) | CA1CA2GAAHDAC6HDAC1 | |
| SCHEMBL22157825 | 0.87 | CYP2D6 (0.33) | CA1CA2GAAHDAC6HDAC1 | |
| SCHEMBL18796463 | 0.86 | CA12 (0.39) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL29083797 | 0.83 | AAK1 (0.35) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL29083800 | 0.83 | AAK1 (0.35) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL3836605 | 0.82 | CYP1A2 (0.37) | CYP1A2CYP2C9CYP2C19HTTNFKB1 | |
| SCHEMBL15290576 | 0.82 | CA12 (0.36) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL27862436 | 0.81 | CA12 (0.35) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL1163137 | 0.80 | MEN1 (0.34) | CA12CA1CA2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104306974-B | The method of the ephrosis for the treatment of contrast agent induction | 诺华股份有限公司 | 2017-06-13 | — | — | CN | disclosed |
| EP-2594556-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2594557-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2594557-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2594556-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| CN-103896796-B | As the alanine derivatives of the replacement of enkephalinase inhibitor | NOVARTIS AG (CH) | 2016-04-27 | — | — | CN | disclosed |
| CN-102574801-B | Substituted aminopropionic acid derivatives as enkephalinase inhibitors | NOVARTIS AG (CH) | 2016-04-27 | — | — | CN | disclosed |
| CN-103313708-B | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2016-03-23 | — | — | CN | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2435409-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136493-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | CA12 3361/4885CA1 2263/4885CA2 767/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | CA12 433/4885CA1 408/4885CA2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.